Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$23.53 -1.3%	$22.18	$13.40 ▼ $25.23	$3.94B	0.7	1.63 million shs	1.75 million shs
ACLX Arcellx	$71.14 -0.4%	$66.67	$47.86 ▼ $107.37	$3.92B	0.28	404,218 shs	330,989 shs
AKRO Akero Therapeutics	$48.37 -1.0%	$52.04	$21.34 ▼ $58.40	$3.86B	-0.28	872,309 shs	867,371 shs
IOVA Iovance Biotherapeutics	$2.68 +4.3%	$2.14	$1.64 ▼ $12.51	$894.94M	0.87	25.14 million shs	16.65 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-1.26%	+1.20%	+10.78%	+57.81%	+23.71%
ACLX Arcellx	-0.35%	-0.24%	+7.24%	+8.53%	+15.09%
AKRO Akero Therapeutics	-0.98%	-4.33%	-6.77%	+7.80%	+80.96%
IOVA Iovance Biotherapeutics	+4.28%	-14.38%	+53.14%	-23.43%	-69.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.988 of 5 stars	3.4	3.0	0.0	2.5	4.2	2.5
ACLX Arcellx	2.5903 of 5 stars	3.5	2.0	0.0	3.4	2.5	0.0
AKRO Akero Therapeutics	3.9641 of 5 stars	3.5	3.0	4.7	2.9	0.8	0.0
IOVA Iovance Biotherapeutics	4.4473 of 5 stars	4.2	1.0	4.2	2.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$28.13	19.53% Upside
ACLX Arcellx	3.07	Buy	$114.31	60.68% Upside
AKRO Akero Therapeutics	3.00	Buy	$82.50	70.56% Upside
IOVA Iovance Biotherapeutics	2.33	Hold	$12.22	356.05% Upside

Current Analyst Ratings Breakdown

Latest IOVA, AKRO, ACLX, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	ACLX Arcellx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$93.00 ➝ $133.00
7/24/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $34.00
7/23/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/15/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/17/2025	ACLX Arcellx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$110.00
6/16/2025	ACLX Arcellx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.11	$0.70 per share	33.38	$4.40 per share	5.35
ACLX Arcellx	$107.94M	36.32	N/A	N/A	$8.41 per share	8.46
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
IOVA Iovance Biotherapeutics	$164.07M	5.45	N/A	N/A	$2.33 per share	1.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	17.18	30.96	6.54	22.97%	17.46%	10.75%	8/6/2025 (Estimated)
ACLX Arcellx	-$107.35M	-$2.99	N/A	N/A	N/A	-211.46%	-35.27%	-22.73%	8/14/2025 (Estimated)
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.24	N/A	N/A	N/A	-176.49%	-49.71%	-39.18%	8/7/2025 (Estimated)

Latest IOVA, AKRO, ACLX, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACLX Arcellx	-$1.03	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	AKRO Akero Therapeutics	-$0.95	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	IOVA Iovance Biotherapeutics	-$0.29	N/A	N/A	N/A	$67.14 million	N/A
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	N/A	N/A	N/A	$263.07 million	N/A
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/8/2025	Q1 2025	IOVA Iovance Biotherapeutics	-$0.25	-$0.36	-$0.11	-$0.36	$83.40 million	$49.32 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
ACLX Arcellx	N/A	4.93	4.93
AKRO Akero Therapeutics	0.03	16.80	16.80
IOVA Iovance Biotherapeutics	N/A	4.18	3.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ACLX Arcellx	96.03%
AKRO Akero Therapeutics	N/A
IOVA Iovance Biotherapeutics	77.03%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
ACLX Arcellx	8.35%
AKRO Akero Therapeutics	7.07%
IOVA Iovance Biotherapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable

IOVA, AKRO, ACLX, and ACAD Headlines

Recent News About These Companies

Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges

August 1 at 10:02 AM | finance.yahoo.com

Iovance Biotherapeutics (IOVA) Projected to Post Earnings on Thursday

August 1 at 5:59 AM | marketbeat.com

Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs

August 1 at 5:01 AM | msn.com

Iovance Biotherapeutics (IOVA) Names Corleen Roche as New CFO

July 31 at 6:58 PM | finance.yahoo.com

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 5.3% - What's Next?

July 31 at 2:54 PM | marketbeat.com

Is Iovance Biotherapeutics Stock Due for a Big Rally?

July 30 at 6:01 AM | fool.com

This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy?

July 29, 2025 | msn.com

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 10.2% - Time to Sell?

July 25, 2025 | marketbeat.com

Iovance Biotherapeutics Is Waking Up - Price Action Screams Breakout, But Fundamentals Demand Patience

July 25, 2025 | seekingalpha.com

2IOVA : Analyst Expectations For Iovance Biotherapeutics's Future

July 24, 2025 | benzinga.com

Here’s why Iova stock surged 32% today and why the rally might not be over

July 24, 2025 | msn.com

Iovance climbs after FDA rejection for Replimune’s skin cancer drug

July 24, 2025 | msn.com

Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 32.8% - Still a Buy?

July 24, 2025 | marketbeat.com

Iovance Biotherapeutics Target of Unusually Large Options Trading (NASDAQ:IOVA)

July 24, 2025 | marketbeat.com

Iovance Biotherapeutics Sees Unusually Large Options Volume (NASDAQ:IOVA)

July 24, 2025 | americanbankingnews.com

Here's why Iova stock surged 32% today and why the rally might not be over

July 23, 2025 | invezz.comI

Chardan Capital Reiterates "Buy" Rating for Iovance Biotherapeutics (NASDAQ:IOVA)

July 23, 2025 | marketbeat.com

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Up - Should You Buy?

July 22, 2025 | marketbeat.com

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Hold" by Analysts

July 21, 2025 | marketbeat.com

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug

July 18, 2025 | seekingalpha.com

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 18, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, AKRO, ACLX, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$23.53 -0.30 (-1.26%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$23.17 -0.36 (-1.53%)

As of 08/1/2025 07:12 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Arcellx NASDAQ:ACLX

$71.14 -0.25 (-0.35%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$71.08 -0.06 (-0.08%)

As of 08/1/2025 05:13 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Akero Therapeutics NASDAQ:AKRO

$48.37 -0.48 (-0.98%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$48.32 -0.05 (-0.10%)

As of 08/1/2025 05:46 PM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Iovance Biotherapeutics NASDAQ:IOVA

$2.68 +0.11 (+4.28%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$2.75 +0.07 (+2.46%)

As of 08/1/2025 07:59 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time